Articles from GE HealthCare

GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for the detection of coronary artery disease (CAD), at early adopter imaging centers in the US. This milestone follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today.

GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2024.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at Citi’s 2025 Medtech and Life Sciences Access Day on February 27, 2025 at 2:15pm CT / 3:15 pm ET.

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.

GE HealthCare (Nasdaq: GEHC) has been named to 2025 Fortune World’s Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare today announced the launch of a Care Innovation Hub, a joint research collaboration that aims to address meaningful clinical challenges in three key areas: accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease, and precision oncology. The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care.

Sutter Health and GE HealthCare (Nasdaq: GEHC) today announced a seven-year strategic enterprise partnership, known as a Care Alliance, that aims to increase access to innovative imaging services and create a more seamless and coordinated experience for clinicians and patients across the Sutter Health system. The long-term collaboration will increase access to essential diagnostic care across California, providing patients with advanced technology in their own communities that can help enable quicker appointment scheduling, accelerated diagnostic imaging scan results, early diagnoses, greater convenience, and more consistent and timely care. This Care Alliance marks one of GE HealthCare's largest ever enterprise strategic partnerships.

GE HealthCare (Nasdaq: GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep learning image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America (RSNA) 2024 Annual Meeting, in Chicago, IL. Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of burnout experienced by clinicians, GE HealthCare developed the technologies to deliver exceptional image quality, reduce scan times, and support improved patient outcomes.

GE HealthCare (Nasdaq: GEHC) announced today the 510(k) submission to the U.S. Food and Drug Administration for CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clearance, will be demonstrated at the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from December 1-4 in Chicago.

GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.

GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially launched in 2023 for Cardiac MRI, Sonic DL provides up to 12 times scan acceleration while maintaining diagnostic qualityiii. Now, GE HealthCare is extending Sonic DL to 3D volumetric imaging, designing it to broaden its applicability to brain, spine, orthopedic and body exams, in addition to cardiac. This expansion is intended to retain the same impressive 12x acceleration and reduce scan times by up to 86%.

At the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from Dec. 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) will exhibit more than 40 innovations, including several key artificial intelligence (AI)-enabled technologies to optimize patient care and increase operational efficiencies.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

GE HealthCare (Nasdaq: GEHC) announces additional clinical applications now available as part of the OEC 3D mobile CBCT C-arm portfolio to help enable precise and efficient imaging during endoscopic bronchoscopy procedures in the practice of interventional pulmonology.

GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance.

GE HealthCare (Nasdaq: GEHC) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed Journal of Clinical Anesthesia, highlighting performance of the wireless and wearable Portrait™ Mobile monitoring solution in the post-surgical ward environment.

GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions.

GE HealthCare (Nasdaq: GEHC) today announced an initiative with AMN Healthcare aimed at helping address the critical shortage of radiologic technologists (rad tech) in the healthcare industry. This initiative helps healthcare providers meet their immediate staffing needs through AMN Healthcare’s comprehensive workforce solutions and GE HealthCare’s innovative technologies and training expertise.

GE HealthCare (Nasdaq: GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required.

GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024.

GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare’s broader AI and digital strategy, which is focused on integrating AI into medical devices, building AI applications that enhance decision-making across the care journey and disease states, and using AI to support better outcomes and operational efficiencies system-wide. The company’s investment in cloud technology underpins this strategy, providing the computing power to drive the development of AI at scale.

GE HealthCare (Nasdaq: GEHC) today announced CareIntellect for Oncology, a new cloud-first application that brings together multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. The application also surfaces relevant data allowing care teams to quickly understand disease progression and flag potential deviations from the treatment plan to help the clinician determine potential next steps and inform proactive interventions. The application, which is planned to be available to customers in U.S. next year, will initially focus on prostate and breast cancer. It organizes structured and unstructured data (e.g., medical images, medical records, notes, and device readings), summarizes complex medical histories, supports treatment response assessments, helps assess clinical trial eligibility, and tracks adherence to treatment protocols in an easy-to-navigate view. This is the first application within GE HealthCare’s new CareIntellect offering of clinical and operational applications designed to help healthcare providers quickly and easily install new applications without having to take a costly and time-consuming product-by-product integration approach.

GE HealthCare (Nasdaq: GEHC), the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation (CAFF), teamed up to launch a new philanthropic endeavor, Powering Milwaukee Forward, aimed at improving access to basic needs within Milwaukee’s underserved communities. The initiative will grant 10 area nonprofits a total of $1 million.

GE HealthCare (Nasdaq: GEHC) today announced the launch of the new Versana Premier™, the latest release within the Versana ultrasound family of reliable, affordable, easy-to-use, and versatile ultrasound systems. Versana Premier offers automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy, all while delivering an effortless user experience and helping clinicians best meet their patient needs.i The Versana Premier is designed to meet the multi-purpose needs of healthcare professionals across diverse clinical specialties and care areas, including general practice, OBGYN, musculoskeletal (MSK), and cardiology.

GE HealthCare integrates third party artificial intelligence (AI)-enabled application orchestration feature into True PACS and Centricity PACS. 1 In collaboration with Blackford, the new AI-enabled offerings help radiologists with their workload which could help lead to quicker diagnosis and treatment for patients. The collaboration is intended to offer health care providers an AI-enabled platform with a catalogue of third-party AI applications that span across various clinical area use cases, ranging from mammography to lung scans. 2

GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

GE HealthCare announces the commencement, and its leading industrial role, in Thera4Care, an initiative aimed at revolutionizing the use of theranostics to broaden patient access in Europe. The €25.3 million project gathers 29 partners from top European academic and clinical sites, small and medium-sized enterprises, and patient advocacy groups.

GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. The results, which will be used to support ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported, according to an abstract presented at the 2024 bi-annual Contrast Media Research symposium in Oslo, Norway.

GE HealthCare (Nasdaq: GEHC) today announced its latest innovations in radiation oncology that will be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference in Washington, DC. These novel solutions aim to improve the entirety of the radiation therapy workflow for clinicians and cancer patients.

Today, GE HealthCare (Nasdaq: GEHC) announced the CE marks of its Vscan Air™ SL wireless handheld ultrasound system with Caption AI™ (Vscan Air SL with Caption AI), an artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care, as well as ECG-less Cardiac computed tomography (CT) scanning on its Revolution Apex™ platform, which allows clinicians to acquire cardiac images without the aid of the patients’ electrocardiogram (ECG) signal/trace. Both technologies will be showcased at the European Society of Cardiology (ESC) Congress, in London, August 30-September 2, 2024.

GE HealthCare (Nasdaq: GEHC) today announced the publication of the MASTER trial results in the peer-reviewed journal Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration for surgical patients.1* End-tidal Control software automatically achieves and maintains clinician-set targets of end-tidal anesthetic agent and oxygen concentrations. The results highlight End-tidal Control’s performance in achieving and maintaining targeted agent and oxygen concentrations during anesthesia delivery compared to conventional manual control.

GE HealthCare today announced a collaboration with the University of California San Diego School of Medicine to investigate advanced magnetic resonance imaging (MRI) protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians. The goal of the project is to elevate women’s pelvic health, filling an important gap in medical research and care. Its results have the potential to enable clinicians to make more informed decisions, diagnose diseases and conditions faster and provide increased access to quality pelvic care for women.

GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2024.

Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (Nasdaq: GEHC) announced HHNM as the first location in the United States to install GE HealthCare’s latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVD). HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aortic valve replacements, balloon and coronary angioplasties and more.

Today GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc., a leading clinical augmented reality med-tech company, announced the successful first installation and clinical cases using the OmnifyXR Interventional Suite1 at North Star Vascular and Interventional in Minneapolis, Minnesota. This innovative augmented reality-based interventional radiology suite combines a holographic heads-up display streaming live medical imaging, 3D anatomy model visualization and advanced imaging technologies, while enabling the opportunity for remote collaboration to help advance the delivery of precision care across a variety of interventional procedures.

GE HealthCare (Nasdaq: GEHC) announced today that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale. This also highlights the depth of internal talent that GE HealthCare is building to strengthen focus on delivering for patients and customers. These changes will be effective July 1, 2024.

GE HealthCare once again joins the world’s top medical and academic institutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting to discuss today’s healthcare landscape and announce new precision care tools to meet providers’ most pressing needs – namely the accessibility of technologies and solutions for the global practice of personalized medicine.

 

GE HealthCare (Nasdaq: GEHC), a leading medical technology innovator, and Tampa General Hospital (TGH), one of the nation’s leading academic health systems, continue to strengthen their long-term partnership by announcing an agreement to deploy GE HealthCare’s Imaging and Ultrasound technology solutions to benefit clinicians and patients in TGH Imaging’s outpatient facilities across the state of Florida.

GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of artificial intelligence (AI) enabled medical devices for the third year in a row with 72 listed 510(k) clearances or authorizations to date in the United States. GE HealthCare also topped the list when it was updated by the FDA in 2022 and 2023.

Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD). Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform. The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians.

GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY. GE HealthCare’s management team will present its growth strategies, technology portfolio, and vision for its businesses via a live webcast and will be accessible at https://investor.gehealthcare.com/news-events/events. More information, including registration details, will be available as the date draws closer.

GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems. Neuroscience, particularly in the study of psychiatric diseases and neurological disorders such as Alzheimer’s, has been constrained by technological and biological limitations, leaving many aspects of the brain structure and functionality largely unexplored.

GE HealthCare (Nasdaq: GEHC), is announcing that its Vice President and Chief Financial Officer, Jay Saccaro will be presenting at the following upcoming investor conferences.

GE HealthCare (Nasdaq: GEHC) today announced Revolution RT,i a new radiation therapy computed tomography (CT) solution with innovative hardware and software solutions to help increase imaging accuracy, while simplifying simulation workflow for a more personalized and seamless oncology care pathway experience for clinicians and patients. The new Revolution RT is being unveiled at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024 Congress in Glasgow, along with an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy (iRT) platform, which interfaces with the Spectronic magnetic resonance imaging (MRI) Planner. Additionally, the company will showcase the newly acquired MIM Software portfolio, as well as other key innovations from GE HealthCare.

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the first quarter ended March 31, 2024.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support timely clinical decisions. As the next evolution of the DINAMAP legacy, Portrait VSM utilizes the SuperSTAT non-invasive blood pressure algorithm to provide precise and accurate measurement readings. Through its wireless connectivity and seamless EMR integration, the portable vital signs monitor was designed with the user workflows in mind, offering customized Early Warning Scores (EWS) and enabling care teams to focus on taking care of their patients by automating routine tasks.

Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analysis and artificial intelligence (AI) solutions – GE HealthCare is proud to announce the expansion of its relationship with Elekta (EKTA-B.ST), a leader in precision radiation oncology. Together, the companies aim to accelerate innovation in software solutions that will help improve workflows, increase throughput, and enhance user experience for clinicians, while also enabling greater precision in treatment and less time spent at the hospital for patients.

GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health. These latest systems combine high-performance hardware with flexible scalable software to help increase clinicians’ confidence in their diagnostic and treatment determinations.

Today the Radiological Society of North America (RSNA) and GE HealthCare (Nasdaq: GEHC) announced their collaboration to provide mammography technology, training and educational tools to radiologists at Muhimbili National Hospital (MNH), part of the Muhimbili University of Health and Sciences (MUHAS), in Tanzania to improve access to screening and help clinicians lower the country’s breast cancer mortality rate.

GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024. This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.

GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL. Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings. Vscan Air SL with Caption AI will debut at the 2024 American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6 – 8, 2024 in Atlanta.

Less than three months after signing an agreement to acquire MIM Software Inc. (“MIM Software”), GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company") (Nasdaq: GEHC) is proud to announce the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

GE HealthCare (Nasdaq: GEHC) today announced the launch of Prostate Volume Assist (PVA) urology-based artificial intelligence (AI) software feature. As a global leader in ultrasound-guided solutions in urology, this AI-based software feature is designed to support clinicians in prostate imaging, biopsies and guiding treatment. This new feature assists urologists by offering a solution that improves workflow and quickly captures prostate volume. The added functionality with PVA can determine calculations and measurements of the organ with an automated, one-click process.

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology. The vendor-agnostic, multi-modality nCommand Lite system will be distributed exclusively by GE HealthCare and will provide remote patient scanning support, remote access for viewing/review of images*, as well as the ability to connect to remote experts who can provide real-time guidance to the licensed technologist operating the scanner. Off-site experts can use these features to aid in training, procedure assessment and scanning parameter management. IONIC Health’s nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT), and positron emission tomography/CT (PET/CT) scanning.

GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT. The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.

Building on a long-term artificial intelligence (AI) collaboration, GE HealthCare used NVIDIA technology to develop its recent research model SonoSAMTrack1, which combines a promptable foundation model for segmenting objects on ultrasound images called SonoSAM1. SonoSAMTrack focuses on segmenting anatomies, lesions, and other essential areas in ultrasound images. SonoSAMLite is a streamlined version of SonoSAMTrack.

GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and Connecticut-based Hartford HealthCare today announced that they have renewed a seven-year collaboration that began in 2016 to now extend through 2030, aiming to advance the healthcare system’s mission to provide personalized coordinated quality care. The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.

Today, GE HealthCare (Nasdaq: GEHC) a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, announced the establishment of its philanthropic entity, the GE HealthCare Foundation. The Foundation will operate as a charitable organization, incorporated separately from GE HealthCare, focused on advancing equitable access to precision healthcare.

GE HealthCare (Nasdaq: GEHC) will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition in Orlando, FL from March 11-15, 2024.

GE HealthCare (Nasdaq: GEHC) today announced its latest innovation in ultrasound with the launch of its next-level LOGIQ ultrasound portfolio—including the new LOGIQ Totus—highlighting the company’s progress in advancing precision care. LOGIQ, is a trusted companion in general ultrasound imaging and has supported clinicians in delivering high-quality, patient-driven innovation for more than 30 years. The elevated LOGIQ portfolio innovative new features and advanced artificial intelligence (AI) tools are designed to address the evolving needs of healthcare providers with easy imaging, efficient workflow and Verisound digital and AI solutions including reporting, fleet management, AI and collaboration tools.

GE HealthCare (Nasdaq: GEHC) today announced a collaboration with OSF HealthCare, an integrated health system caring for patients throughout Illinois and Michigan, and Pointcore, Inc., a healthcare management and non-clinical shared services company, to help increase clinical and operational efficiencies, standardize care delivery models and improve patient outcomes across OSF HealthCare. This alliance will leverage GE HealthCare’s expertise and innovative technology and Pointcore’s decades of experience managing nonclinical matters for hospitals and clinics. It will also support the Mission of OSF HealthCare to deliver exceptional care to patients in the communities they serve.

GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be presenting at the following upcoming investor conferences.

GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest that are needed to optimize multi-site outpatient imaging networks for success.

Insertion of Fourth Quarter 2023 P&L labeled "Consolidated and Combined Statements of Income" following the 2024 Guidance information.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Novii™+ Wireless Patch Solution. The antepartum and intrapartum maternal and fetal monitor noninvasively measures and displays fetal heart rate, maternal heart rate and uterine activity, so care teams can have a real-time view of patient data. Through its belt-free and wireless design, Novii+ enables mobility and freedom for mothers to support the laboring experience. Additionally, studies have shown upright positions and walking may help decrease the length of labor.2

GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias.

GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.

GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023 payable on February 15, 2024 to all shareholders of record as of January 16, 2024.

GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and AirStrip, a vendor-agnostic clinical surveillance technology company and a member of the Nantworks group of AI driven companies, announced today a joint commercialization agreement. GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that healthcare systems can purchase together.

Through its leading imaging solutions and commitment to innovation, GE HealthCare (NASDAQGEHC) remains at the forefront of leveraging deep learning, a subset of artificial intelligence (AI), to benefit a multitude of clinicians and patients. True Enhance DLi for CT is the latest addition to GE HealthCare’s growing Effortless Recon DL portfolio of deep learning-based solutions – which also includes AIR Recon DL for MR and PET/MR, Sonic DL for MR, TrueFidelity DL for CT, Precision DL for PET/CT, and Helix for X-ray – with the goal of improving image quality and helping to better inform clinical decision-making for improved patient outcomes.

Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX. The updated PTX algorithm expands Critical Care Suite’s on-device triage capabilities by providing immediate notification of the presence or absence of pneumothorax, as well as an overlay display both on-device and in PACS to assist with PTX localization.